Kymab Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 141

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1.45B

Kymab General Information

Description

Developer of novel human antibody-based therapies in a broad range of indications. The company offers fully human monoclonal antibody therapeutics to maximize the diversity of human antibodies produced in response to immunization with antigens, thereby enabling healthcare providers to use novel therapeutic antibodies to cure cancer and autoimmune hematological diseases.

Contact Information

Website
www.kymab.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • The Bennet Building (B930)
  • Babraham Research Campus
  • Cambridge CB22 3AT
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Acquirer
Sanofi
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • The Bennet Building (B930)
  • Babraham Research Campus
  • Cambridge CB22 3AT
  • England, United Kingdom

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kymab Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 08-Apr-2021 $1.45B Completed Generating Revenue
5. Later Stage VC 24-Jun-2019 Completed Clinical Trials - General
4. Grant 09-Jan-2017 Completed Clinical Trials - General
3. Later Stage VC (Series C) 24-Nov-2016 Completed Clinical Trials - General
2. Later Stage VC (Series B) 05-Jun-2015 $89.1M $119M Completed Clinical Trials - General
1. Early Stage VC (Series A) 13-Jul-2010 $30.1M $30.1M Completed Startup
To view Kymab’s complete valuation and funding history, request access »

Kymab Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Convertible Preferred
Convertible Preferred
Series C
Series B 30,403,646 $0.001266 $2.44 $2.44 1x $2.44 22.6%
Series A 20,090,000 $0.001266 $1.27 $1.27 1x $1.27 14.93%
To view Kymab’s complete cap table history, request access »

Kymab Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel human antibody-based therapies in a broad range of indications. The company offers fully human monocl
Drug Discovery
Cambridge, United Kingdom
141 As of 2022

Abingdon, United Kingdom
 

Schlieren, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kymab Competitors (96)

One of Kymab’s 96 competitors is Adaptimmune Therapeutics, a Formerly VC-backed company based in Abingdon, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Memo Therapeutics Venture Capital-Backed Schlieren, Switzerland
Nektar Therapeutics Formerly VC-backed San Francisco, CA
Metacrine Formerly VC-backed San Diego, CA
NexImmune Formerly VC-backed Gaithersburg, MD
You’re viewing 5 of 96 competitors. Get the full list »

Kymab Patents

Kymab Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240392021-A1 Pharmaceutical formulations containing anti-ox40l antibodies Pending 14-Apr-2023
US-20240294651-A1 Antibodies Pending 30-Jan-2023
GB-202204291-D0 Treatment of atopic dermatitis Inactive 25-Mar-2022
GB-202204211-D0 Treatment of atopic dermatitis Inactive 24-Mar-2022
GB-202117101-D0 Antibodies for use as therapeutics against bacterial infections Inactive 26-Nov-2021
To view Kymab’s complete patent history, request access »

Kymab Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kymab Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bill & Melinda Gates Foundation Not-For-Profit Venture Capital Minority
Cygnum Capital Merchant Banking Firm Minority
LifeArc Venture Capital Minority
Malin Corporation Venture Capital Minority
ORI Capital Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
14M Genomics Cambridge, United Kingdom 2014

Kymab FAQs

  • When was Kymab founded?

    Kymab was founded in 2010.

  • Where is Kymab headquartered?

    Kymab is headquartered in Cambridge, United Kingdom.

  • What is the size of Kymab?

    Kymab has 141 total employees.

  • What industry is Kymab in?

    Kymab’s primary industry is Drug Discovery.

  • Is Kymab a private or public company?

    Kymab is a Private company.

  • What is the current valuation of Kymab?

    The current valuation of Kymab is .

  • What is Kymab’s current revenue?

    The current revenue for Kymab is .

  • How much funding has Kymab raised over time?

    Kymab has raised $258M.

  • Who are Kymab’s investors?

    Bill & Melinda Gates Foundation, Cygnum Capital, LifeArc, Malin Corporation, and ORI Capital are 5 of 8 investors who have invested in Kymab.

  • Who are Kymab’s competitors?

    Adaptimmune Therapeutics, Memo Therapeutics, Nektar Therapeutics, Metacrine, and NexImmune are some of the 96 competitors of Kymab.

  • When was Kymab acquired?

    Kymab was acquired on 08-Apr-2021.

  • Who acquired Kymab?

    Kymab was acquired by Sanofi.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »